Table 1.
Age (years) | |
Mean ± SD | 40 ± 14 |
Median | 39 |
Range | 16–78 |
Gender | |
Female | 78% |
Histology | |
Papillary | 96% |
Poorly differentiated | 2% |
Follicular | 2% |
Tumor size (cm) | |
Mean ± SD | 1.9 ± 1.3 |
Median | 1.6 |
Range | 0.2–9.0 |
Extent of neck dissection at thyroidectomy | |
Central only | 34% |
Lateral only | 10% |
Both central and lateral compartments | 13% |
No lymph node dissection | 43% |
AJCC stage | |
I | 72% |
II | 4% |
III | 14% |
IVa | 10% |
ATA initial risk classification | |
Low | 27% |
Intermediate | 65% |
High | 8% |
Response to therapy classification | |
Excellent | 1% |
Acceptable | 67% |
Incomplete | 24% |
Cannot classify | 8% |
RAI ablation | |
Yes | 84% |
No | 16% |
131I activity for ablation (mCi) | |
Mean ± SD | 126 ± 45 |
Median | 146 |
Range | 28–350 |
Follow-up duration (years) | |
Mean ± SD | 7 ± 5 |
Median | 5 |
Range | 2–37 |
Basal thyroglobulin at the time of first postoperative ultrasound (ng/mL) | |
Mean ± SD | 4.8 ± 3.0 |
Median | 0.6 |
Range | <0.6–480 |
Clinical status at final follow-up | |
No evidence of disease | 59% |
No evidence of disease after additional therapy | 11% |
Biochemical persistent/recurrent disease | 17% |
Structural persistent/recurrent disease | 13% |
Disease-specific death | 0% |
Number of ultrasounds on follow-up | |
Mean ± SD | 5 ± 2 |
Median | 4 |
Range | 3–16 |
Time from initial surgery to first postoperative ultrasound done at MSKCC (months) | |
Mean ± SD | 33 ± 46 |
Median | 18 |
Range | 3–312 |
Increase in size of at least one thyroid bed nodule over follow-up | 9% |
SD, standard deviation; AJCC, American Joint Committee on Cancer; ATA, American Thyroid Association; RAI, radioactive iodine; MSKCC, Memorial Sloan-Kettering Cancer Center.